SPARCL: Stroke Prevention by Aggressive Reduction in Cholesterol Levels

principal researchers

Pierre Amarenco (Denis Diderot University)

K. Michael Welch (Rosalind Franklin University of Medicine and Science)

Data custodian

SPARCL Investigators

Funding

Pfizer Inc.

Key Publications

• Design and baseline characteristics paper: Cerebrovasc Dis 2003;16:389–395

• Main results: N Engl J Med 2006;355:549-59

• Effects of intense LDL-C Reduction in Patients with stroke or TIA: Stroke 2007;38:3198-3204

• Hemorrhagic stroke in the SPARCL Study: Neurology 2008;70:2364-70

• SPARCL patients randomized with atherosclerosis: Stroke 2008 Dec;39(12):3297-302

• Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events: Atherosclerosis 2009; 204:515–520

• Statin and outcome (neuroprotective effect) in SPARCL: Stroke 2009 ;40 :3526-31

• Elderly patients in SPARCL: Neurology 2009;72 688-694

• SPARCL trial results by stroke subtypes: Stroke 2009;40:1405-1409

• Relative and cumulative effects of lipid and blood pressure control in the SPARCL Trial: Stroke 2009;40:2486-2492
  

• CHD risk in patients with stroke or TIA and no known CHD: Stroke 2010;41:426-430

• Type 2 diabetes or metabolic syndrome in SPARCL: Arch Neurol. 2011 Oct;68(10):1245-51

• Renal function (nephro-protective effect) in SPARCL trial: Stroke 2014 Oct;45(10):2974-82